Novartis AG (NVSEF) Stock Price & Analysis
Novartis AG (NVSEF) — price $134.20 (-4.78%), as of the Oct 2, 2026 trading session; market cap $255B. Expected results Oct 27, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 33.23× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 27, 2026
Novartis AG · NVSEF · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Novartis spans innovative prescription medicines, generics, biosimilars, active ingredients and biotechnology manufacturing services rather than relying on a uniform drug portfolio. Its case rests on whether broad commercial reach and sustained research spending can keep expanding profit and cash generation while debt remains far above liquid resources.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $134.20 | |
| Change on the day | -4.78% | |
| 52-week range | $120.00 – $171.29 | |
| Market capitalisation | $255B | |
| Price / earnings (trailing) | 21.25 | |
| Shares traded on the day | 1.2K | |
| Beta (volatility vs the S&P 500) | 0.49 | |
| Dividends per share (last 12 months) | $4.74 | |
| Dividend yield (last 12 months) | 3.53% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Novartis AG (NVSEF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the NVSEF film — every key number, told as a short cinematic story
~2 min · open the film
What is Novartis AG (NVSEF), and what does it report?
Short answer · as of
Novartis researches, develops, manufactures and commercializes medicines worldwide.
Research dated 2026-09-12.
Novartis researches, develops, manufactures and commercializes medicines worldwide. Innovative Medicines serves patients and healthcare professionals across areas including neuroscience, immunology, cardiovascular, renal and metabolic disease, while Sandoz supplies generics, biosimilars, anti-infectives, active ingredients and manufacturing services to external partners.
What do the latest results show for Novartis AG (NVSEF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $14.09B.
Research dated 2026-09-12.
Revenue, gross profit, operating profit, net income and diluted earnings all improved from the immediately preceding period, but remained below the comparable earlier period. The rebound therefore reached well beyond sales and appeared clearly in operating and net profit.
The latest earnings release cleared analyst expectations for revenue and earnings after a mixed sequence of beats and misses. On the annual view, revenue and net income advanced while research spending also increased, showing that recent profit growth did not require a retreat from development investment.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $14.09B Jun 30, 2026
- Latest quarter · R&D
- $2.70B Jun 30, 2026
- Latest quarter · SG&A
- $3.17B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $4.63B Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $14.09B | $2.70B | $3.17B | $4.63B |
| Mar 31, 2026 | $12.86B | $2.74B | $3.08B | $3.67B |
| Dec 31, 2025 | $13.44B | $2.86B | $3.46B | $3.78B |
| Sep 30, 2025 | $14.36B | $2.94B | $3.31B | $4.50B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $14.41B Jul 21, 2026
- Latest report · revenue estimate
- $14.08B Jul 21, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 21, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 21, 2026 | $14.41B | $14.08B | $2.4100 | $2.1700 |
| Apr 28, 2026 | $13.11B | $13.46B | $1.9900 | $2.1000 |
| Feb 4, 2026 | $13.34B | $13.46B | $2.0300 | $1.9900 |
| Oct 28, 2025 | $13.91B | $13.88B | $2.2500 | $2.2700 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $14.09B | $3.19B | $1.67 (diluted) |
| Q1 FY2026 | $12.86B | $3.09B | $1.62 (diluted) |
| Q4 FY2025 | $13.44B | $2.43B | $1.26 (diluted) |
| Q3 FY2025 | $14.36B | $3.93B | $2.00 (diluted) |
What are the financial strengths and risks for Novartis AG (NVSEF)?
Short answer
Cash and short-term investments were $7.67B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $5.74B for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow stayed positive throughout the displayed run and comfortably exceeded capital expenditure in the latest period. Trailing margins and free-cash-flow yield reinforce the picture of a profitable, cash-generative pharmaceutical operation.
Debt substantially exceeds cash and investments, short-term coverage ratios remain below full coverage, and cash has fallen materially across the reported window despite a recent recovery. Weaker prescription demand would therefore meet substantial research and commercial spending alongside a meaningful debt burden, reducing room for error even while current cash generation remains strong.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $5.74B Jun 30, 2026
- Previous quarter · operating cash flow
- $3.60B Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $5.74B | −$313.85M |
| Mar 31, 2026 | $3.60B | −$339.28M |
| Dec 31, 2025 | $2.15B | −$625.58M |
| Sep 30, 2025 | $6.57B | −$831.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Novartis AG (NVSEF)?
Short answer · as of
The next earnings report is expected on Oct 27, 2026.
Research dated 2026-09-12.
At the next release, watch whether revenue and earnings clear consensus while operating profit and operating cash flow preserve their latest rebound. Cash also needs monitoring against debt: stabilization would strengthen the financial picture, while renewed erosion would make the leverage gap harder to dismiss.
Consensus assumes revenue and earnings continue rising across the forecast horizon. Stagnant sales, weaker profit conversion or heavier cash use would conflict with that trajectory; continued growth paired with resilient cash generation would support it.
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is Novartis AG scored?
Research dated 2026-09-12.
Novartis combines the economics of an innovative-medicine developer with activities more typical of a generic and biosimilar supplier. It also produces finished-dose medicines, active ingredients and intermediates for external partners and offers biotechnology manufacturing services, so consolidated revenue blends patented prescription products with broader pharmaceutical supply and service activity.
That operating breadth differs from a pure research-led drug developer and from a pure generic producer. The financial profile still carries the heavy research commitment and high margins associated with innovative pharmaceuticals, while the balance sheet adds leverage that a comparison based only on product breadth would miss.
| Company | Price | Market value | Score |
|---|---|---|---|
| $419.92 Oct 2, 2026 | $335B | — Model unavailable | |
| $189.90 Sep 25, 2026 | $294B | — Model unavailable | |
| $22.77 Oct 2, 2026 | $91.2B | — Model unavailable | |
| $23.50 Oct 2, 2026 | $229B | — Model unavailable | |
| $37.01 Oct 2, 2026 | $164B | — Model unavailable | |
| $403.04 Oct 2, 2026 | $218B | — 5-pillar · not comparable | |
| $144.30 Oct 2, 2026 | $356B | — 5-pillar · not comparable | |
| $144.74 Oct 2, 2026 | $179B | — 5-pillar · not comparable | |
| $27.80 Oct 2, 2026 | $158B | — 5-pillar · not comparable | |
| $262.82 Oct 2, 2026 | $464B | — 5-pillar · not comparable | |
| $61.15 Oct 2, 2026 | $125B | — 5-pillar · not comparable | |
| $256.03 Oct 2, 2026 | $617B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about Novartis AG (NVSEF)?
NVSEF Healthcare Stock FAQ
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Novartis sell beyond Innovative Medicines?
Sandoz supplies generic and biosimilar medicines, anti-infectives, active ingredients and intermediates, while also providing biotechnology manufacturing services to external partners.
How does Sandoz change the way Novartis revenue should be read?
Consolidated revenue reflects more than advanced prescription medicines. It also includes finished-dose generics, biosimilars, pharmaceutical ingredients and manufacturing services, giving Novartis a broader demand base than a pure innovative-drug developer.
Does Novartis generate cash while funding its research base?
Operating cash flow remained positive across the displayed periods and exceeded capital expenditure, while annual research spending increased alongside revenue and net income. Cash generation is therefore substantial, although debt remains well above liquid resources.
What does the Alnylam inclisiran collaboration add to Novartis?
The agreement covers development, production and commercialization of inclisiran, extending Novartis through a partnered medicine rather than an internally controlled program alone.
What is the NVSEF stock price today?
The last price recorded on this page for Novartis AG (NVSEF) is $134.20, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does NVSEF pay a dividend?
Yes. Novartis AG (NVSEF) shows a trailing 12-month dividend yield of 3.53%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (67 figures)
The 67 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Lichtstrasse 35, Basel, V8, CH 4056 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Lichtstrasse 35, Basel, BS, 4056, CH". |
FMP — 59 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 27, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $134.20 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T06:34:22.479Z. | |
px.change | Change on the day | -4.78% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $255B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T06:34:21.348Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$6.73 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 21.25 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.49 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Vasant Narasimhan | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 75,267 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.q_revenue | Revenue, Q2 FY2026 | $14.09B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $52.88B, net result $24.02B; FY2022 revenue $51.83B, net result $6.96B; FY2023 revenue $46.66B, net result $14.85B; FY2024 revenue $51.72B, net result $11.94B; FY2025 revenue $57.13B, net result $14.65B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 74.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $14.09B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $2.70B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $3.17B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $4.63B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $12.86B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $2.74B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $3.08B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $3.67B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $13.44B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $2.86B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $3.46B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $3.78B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $14.36B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $2.94B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $3.31B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $4.50B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-21.revenue_actual | Revenue · reported — report date 2026-07-21 | $14.41B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.revenue_estimated | Revenue · estimate — report date 2026-07-21 | $14.08B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_actual | EPS · reported — report date 2026-07-21 | $2.4100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_estimated | EPS · estimate — report date 2026-07-21 | $2.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_actual | Revenue · reported — report date 2026-04-28 | $13.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_estimated | Revenue · estimate — report date 2026-04-28 | $13.46B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_actual | EPS · reported — report date 2026-04-28 | $1.9900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_estimated | EPS · estimate — report date 2026-04-28 | $2.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_actual | Revenue · reported — report date 2026-02-04 | $13.34B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_estimated | Revenue · estimate — report date 2026-02-04 | $13.46B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.eps_actual | EPS · reported — report date 2026-02-04 | $2.0300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.eps_estimated | EPS · estimate — report date 2026-02-04 | $1.9900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_actual | Revenue · reported — report date 2025-10-28 | $13.91B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_estimated | Revenue · estimate — report date 2025-10-28 | $13.88B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_actual | EPS · reported — report date 2025-10-28 | $2.2500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_estimated | EPS · estimate — report date 2025-10-28 | $2.2700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $7.67B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $5.74B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $2.37B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $48.91B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 6.42× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $5.74B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $3.60B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$313.85M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$339.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $2.15B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$625.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $6.57B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$831.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $120.00 – $171.29 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 33.23× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $7.67B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $4.74 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.53% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-21.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($14.41B) with the recorded estimate ($14.08B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-21.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($2.4100) with the recorded estimate ($2.1700) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-21. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-21.revenue_actual,earn.history.depth.2026-07-21.revenue_estimated,earn.history.depth.2026-07-21.revenue_actual.comparison,earn.history.depth.2026-07-21.eps_actual.comparison,earn.history.depth.2026-07-21.eps_actual,earn.history.depth.2026-07-21.eps_estimated,earn.history.depth.2026-04-28.revenue_actual,earn.history.depth.2026-04-28.revenue_estimated,earn.history.depth.2026-04-28.eps_actual,earn.history.depth.2026-04-28.eps_estimated,earn.history.depth.2026-02-04.revenue_actual,earn.history.depth.2026-02-04.revenue_estimated,earn.history.depth.2026-02-04.eps_actual,earn.history.depth.2026-02-04.eps_estimated,earn.history.depth.2025-10-28.revenue_actual,earn.history.depth.2025-10-28.revenue_estimated,earn.history.depth.2025-10-28.eps_actual,earn.history.depth.2025-10-28.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | NOVARTIS AG Our market-data provider lists the name as "Novartis AG"; the filer's own record is used here. | 2026-09-12 | OFFICIAL | SEC EDGAR filer record |
| Business description | Novartis AG, a global pharmaceutical enterprise established in 1996 and based in Basel, Switzerland, is engaged in the entire lifecycle of healthcare products, from research and development to manufacturing and worldwide commercialization. The company's operations are divided into two main divisions: Innovative Medicines and Sandoz. The Innovative Medicines segment is dedicated to providing advanced prescription medications to both patients and healthcare professionals. Its extensive product portfolio covers a wide range of therapeutic areas, including ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory conditions, cardiovascular health, renal diseases, and metabolism. Conversely, the Sandoz segment specializes in a comprehensive array of generic and biosimilar products. This involves the creation, production, and distribution of finished dosage form medicines, as well as active ingredients and small molecule pharmaceuticals for external partners. Sandoz also supplies generic drugs for retail, anti-infectives, and crucial active pharmaceutical ingredients (APIs) and intermediates, particularly antibiotics. Additionally, this division is involved in developing protein-based and other biotechnology products, such as biosimilars, and offers biotechnology manufacturing services. Novartis AG also pursues strategic collaborations. It has a licensing and collaboration agreement with Alnylam Pharmaceuticals concerning the development, production, and commercialization of inclisiran. Moreover, the company maintains a clinical partnership with Kura Oncology, Inc. to assess the combined efficacy of Tipifarnib and Alpelisib in treating head and neck squamous cell carcinoma patients. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $48.91B; Liquidity basis: cash and short-term investments; Total liabilities: $79.92B; Cash and short-term investments: $7.67B; Cash and investments: $10.04B; Long-term investments: $2.37B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Employees | Count: 75,267 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-21 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $10.04B; Cash and short-term investments: $7.67B; Long-term investments: $2.37B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $7.67B; Decline: $6.35B; Opening balance: $14.02B; Average change per period: $906.60M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$41.24B; Total debt: $48.91B; Cash and investments: $7.67B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.67; Current ratio: 0.86; Debt to equity: 1.18; Net margin: 23.1%; Gross margin: 74.3%; Operating margin: 29.9%; Return on assets: 10.3%; Return on equity: 29.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-27; EPS estimate: $2.25 per share; Revenue estimate: $14.62B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.